| COMPANY |
Natera, Inc. |
| COURT |
United States District Court for the Western District of Texas |
| CASE NUMBER |
22-cv-00398 |
| JUDGE |
Honorable David A. Ezra |
| CLASS PERIOD |
February 26, 2020 through March 14, 2022 |
| SECURITY TYPE |
Common Stock |
Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Natera, Inc. (“Natera”) (NASDAQ: NTRA) common stock between February 26, 2020 and March 14, 2022, inclusive (the “Class Period”).
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts concerning two of Natera’s core products, Prospera, a non-invasive kidney transplant rejection test, and Panorama, its non-invasive prenatal test. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Panorama, was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of Defendants’ false and misleading claims about Natera’s technology, Natera was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, Defendants’ statements about Natera’s business, operations, and prospects lacked a reasonable basis.
Current Status of Case:
On March 21, 2025, the Court granted Plaintiffs’ Motion for Class Certification. This action is in the discovery phase and is ongoing.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.